Could a Sugar-Blocking pill boost immunotherapy for tough cancers?
NCT ID NCT05913388
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding an experimental pill (GB1211) to the immunotherapy drug pembrolizumab (Keytruda) works better than Keytruda alone for people with advanced melanoma or head and neck cancer. The study will enroll 92 participants and measure how many patients' tumors shrink. GB1211 targets a protein called galectin-3, which may help cancer hide from the immune system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GB1211 (a galectin-3 inhibitor) and pembrolizumab (Keytruda)
- What this could lead to
- If it works, this combination could improve tumor shrinkage rates for people with advanced melanoma or head and neck cancer who have already tried standard treatments.
- What could go wrong
- This is a mid-stage trial with only 92 participants, so results may not apply to everyone. Adding GB1211 could also increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Providence Portland Medical Center
RECRUITINGPortland, Oregon, 97213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?